Endocrine Abstracts

BackgroundThe usage of Immune checkpoint inhibitors such as pembrolizumab grows over time due to their positive effect on survival and quality of life in patients with advanced cancer. The frequency of immune-related adverse events (IRAEs) associated with this drugs grows over time accordingly. Several endocrine-IRAEs of pembrolizumab are described in the literature and the thyroid disfunction is the most common.Case description</p...